Diagnostic Evaluation of Urinary Angiogenin (ANG) and Clusterin (CLU) as Biomarker for Bladder Cancer

Shabayek, Marwa I.; sayed, ola; Attaia, Hanan A.; Awida, Heba A.; Abozeed, Hamdy

doi:10.1007/s12253-014-9765-y

Cited by 30 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies showed that detection of circulating sCLU might improve the identification of people at risk of colorectal cancer [11]; besides, combining detections of serum clusterin and angiogenin (ANG) could have an excellent performance in diagnosis of bladder cancer [12]. On the other hand, some studies found that sCLU overexpression was linked to the poor survival in patients with cervical, ovarian, or lung cancer, indicating that sCLU might be a predictor for the prognosis of malignancies [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma

et al. 2015

View full text Add to dashboard Cite

The upregulation of secretory clusterin (sCLU) is associated with tumor progression by contributing to angiogenesis, chemo-resistance, cell survival, and metastasis. However, its diagnostic or prognostic values for hepatocellular carcinoma (HCC) still remain to be clarified. The average serum sCLU level analyzed by an enzyme-linked immunosorbent assay was significantly higher (P < 0.001) in HCC patients than that in any of cases with cirrhosis, chronic hepatitis, or healthy control. The area under receiver operating characteristic curve and diagnostic sensitivity were 0.75 and 74.7 % in sCLU, and 0.74 and 58.7 % in α-fetoprotein (AFP), respectively. The combining detections of sCLU and AFP rose up to 90.7 % for HCC diagnosis. In liver, sCLU by immunohistochemistry was significantly higher (P < 0.001) in the HCC (77.3 %) group than that in their para-cancerous group (33.3 %). Abnormal serum or tissue sCLU expression was closely associated with tumor-node-metastasis (TNM) classification of malignant tumors and lymph node metastasis, as an independent prognosis factor (hazard ratio, 2.287; 95 % confidence interval, 1.044-5.007; P = 0.039), and higher sCLU expression significantly correlated (χ (2) = 4.252, P = 0.039) with poor survival of HCC patients analyzed by multivariate Cox regression or Kaplan-Meier method, suggesting that abnormal sCLU expression associated with tumor progression could be a potential diagnostic and prognostic biomarker for HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…sCLU is a small stress-induced cytoprotective chaperone protein that plays an important role in cell proliferation, multidrug resistance, metastasis, and tumor progression [24]. Aberrant sCLU expression in the serum or tumor tissues of patients with primary cancers is considered as a useful biomarker for disease diagnosis and surveillance [8,[25][26][27]. In our study, we observed that sCLU was overexpressed in OS tissue relative to non-tumor or non-metastatic tumor tissue, implying that sCLU contributes to OS progression by acting as an oncogene.…”

Section: Discussionmentioning

confidence: 99%

sCLU as prognostic biomarker and therapeutic target in osteosarcoma

Gao

2019

Bioengineered

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most common primary malignant bone tumor. Secretory apolipoprotein J/clusterin (sCLU) is overexpressed in many cancers; however, its role in OS has not been previously investigated. The objectives of this study were to address this question and also to assess the clinical value of sCLU as a prognostic biomarker and therapeutic target by comparing sCLU expression in human OS (n = 106), normal bone (n = 16), fibrous dysplasia (n = 9), and ossifying myositis (n = 11) tissues and by evaluating the effect of sCLU silencing on OS growth, invasion, and chemosensitivity in vitro and in vivo. We found that sCLU was highly expressed in OS tissue specimens, which was positively correlated with metastatic disease and negatively correlated with response to chemotherapy. sCLU knockdown in KHOS cells inhibited proliferation and invasion and increased apoptosis as well as sensitivity to the chemotherapy drug gemcitabine (Gem). In a mouse xenograft model, sCLU depletion suppressed lung metastasis and enhanced the effects of Gem, thereby slowing KHOS tumor growth. These results indicate that sCLU overexpression is a biomarker for malignant transformation of OS and that therapeutic strategies targeting sCLU may be an effective treatment for OS. Highlights• Secretory apolipoprotein J/clusterin (sCLU) is overexpressed in osteosarcoma (OS).• sCLU overexpression is associated with metastasis and chemoresistance.• Silencing sCLU inhibits metastasis and enhances chemosensitivity in OS cells. sCLU is a biomarker for metastatic OS and a potential therapeutic target. ARTICLE HISTORY

show abstract

“…The advantage of these multi-urinary protein biomarkers is evident in high and low-grade diseases [ 70 ]. Some urine markers, including midkine (MDK), synuclein G, CEA cell adhesion molecule 1 (CEACAM1), zinc-alpha-2-glycoprotein (ZAG2) [ 71 ], clusterin (CLU), and ANG, showed improved sensitivity and specificity in diagnosing NMIBC when used in immunoassays and urine cytology [ 72 ]. Levels of CK20 and insulin-like growth factor II (IGF-II) were increased in the urine sediments of NMIBC patients compared to controls [ 73 ].…”

Section: Human Specimens-based Proteomics Biomarkersmentioning

confidence: 99%

Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist

et al. 2020

View full text Add to dashboard Cite

At present, proteomic methods have successfully identified potential biomarkers of urological malignancies, such as prostate cancer (PC), bladder cancer (BC), and renal cell carcinoma (RCC), reflecting different numbers of key cellular processes, including extracellular environment modification, invasion and metastasis, chemotaxis, differentiation, metabolite transport, and apoptosis. The potential application of proteomics in the detection of clinical markers of urological malignancies can help improve patient assessment through early cancer detection, prognosis, and treatment response prediction. A variety of proteomic studies have already been carried out to find prognostic BC biomarkers, and a large number of potential biomarkers have been reported. It is worth noting that proteomics research has not been applied to the study of predictive markers; this may be due to the incompatibility between the number of measured variables and the available sample size, which has become particularly evident in the study of therapeutic response. On the contrary, prognostic correlation is more common, which is also reflected in existing research. We are now entering an era of clinical proteomics. Driven by proteomic-based workflows, computing tools, and the applicability of cross-correlation of proteomic data, it is now feasible to use proteomic analysis to support personalized medicine. In this paper, we will summarize the current emerging technologies for advanced discovery, targeted proteomics, and proteomic applications in BC, particularly in discovery of human-based biomarkers.

show abstract

Diagnostic Evaluation of Urinary Angiogenin (ANG) and Clusterin (CLU) as Biomarker for Bladder Cancer

Cited by 30 publications

References 27 publications

Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma

Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma

sCLU as prognostic biomarker and therapeutic target in osteosarcoma

Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist

Contact Info

Product

Resources

About